Q3 2024 Earnings Call Transcript October 22, 2024 Danaher Corporation beats earnings expectations. Reported EPS is $1.71, ...

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for ...

The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's ...

Interim data from Otsuka's trial of sibeprenlimab indicates a significant reduction in proteinuria in IgA nephropathy ...

Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...

CAL101 is an anti-S100A4 monoclonal antibody (mAb) and Calluna's lead drug candidate Study demonstrated a favorable safety, pharmacokinetic (PK) and immunogenicity profile CAL101 is ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

In recent months, the Delaware Court of Chancery has decided four significant cases regarding merger agreement earnout provisions. Most notably, ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...